An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report 

August 17, 2022

 MedinCell’s annual ESG report goes into detail on the different pillars of its ESG policy, its implementation through concrete and clearly defined objectives, and the evolution of the company’s extra-financial data. 

Access MedinCell’s ESG performance in a nutshell 

Download the 2021-2022 ESG annual report 

About the publication of this report, Christophe Douat, CEO of MedinCell, declared: “What is called CSR is at the heart of our humanist pharma company model and of the shared-value with all our employees since MedinCell was established. It is a virtuous process of continuous improvement at all levels of the company. This year, we implemented an ESG committee at the highest level of governance to guarantee the sustainability of our commitment. We have also improved our extra-financial performance by working on several topics such as transparency, environment, corporate governance, and ethics. And the best is still to come, with the first treatment based on our technology expected to be approved in 2023. Based on excellent clinical trial results, it should have a real impact on the lives of patients with schizophrenia, on caregivers who support them, and on society. This is our “raison d’être”! » 

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.